TELA Bio Net Income 2018-2021 | TELA

TELA Bio net income from 2018 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
TELA Bio Annual Net Income
(Millions of US $)
2020 $-29
2019 $-30
2018 $-30
2017 $-27
TELA Bio Quarterly Net Income
(Millions of US $)
2021-09-30 $-8
2021-06-30 $-8
2021-03-31 $-8
2020-12-31 $-8
2020-09-30 $-8
2020-06-30 $-6
2020-03-31 $-7
2019-12-31 $-7
2019-09-30 $-7
2019-06-30 $-8
2019-03-31 $-8
2018-12-31
2018-09-30 $-5
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.174B $0.018B
TELA Bio Inc. is a commercial stage medical technology company. It is focused on the designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices. TELA Bio Inc. is headquartered in Malvern, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69